Histogen (HSTO)
(Delayed Data from OTC)
$0.35 USD
0.00 (0.26%)
Updated Apr 26, 2024 09:30 AM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
HSTO 0.35 0.00(0.26%)
Will HSTO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HSTO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HSTO
Histogen (HSTO) Upgraded to Strong Buy: Here's What You Should Know
Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?
HSTO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for HSTO
Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering
Histogen files for Chapter 11, seeks liquidation
Histogen files for voluntary Chapter 11 protection
Conatus Pharmaceuticals Inc and Histogen Inc Enter into Definitive Merger Agreement Conference ...
Q4 2018 Conatus Pharmaceuticals Inc Earnings Call Transcript